#### **Overview** Caplin Point Laboratories Ltd is an Indian, fully integrated global pharmaceutical company with a 100% export-oriented business model. Established in 1990 and listed on Indian stock exchanges, it has evolved from a contract manufacturer of basic generics into a research-led, diversified pharma player offering branded generics, specialty molecules, and complex injectables. The company operates across the entire pharmaceutical value chain—from Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) to finished dosage forms, R&D, clinical research (via its CRO arm Amaris Clinical), and direct-to-consumer distribution. It maintains a strong presence in **emerging markets**—especially Latin America and Francophone Africa—while growing aggressively in **regulated markets** such as the United States, Canada, Australia, Mexico, and the European Union through its key subsidiary, **Caplin Steriles Limited (CSL)**. --- #### **Business Model & Strategy** - **Dual-Market Strategy**: - **Emerging Markets (77% of revenue)**: Focused on serving the **Bottom of the Pyramid (BoP)** with high-quality, affordable medicines in underserved geographies, using an **end-to-end, distribution-led model** with owned or acquired subsidiaries. - **Regulated Markets (23% of revenue)**: Transitioning from B2B manufacturing/export to **B2C front-end ownership** via **Caplin Steriles USA Inc. (CSU)**, which launched in 2024–25 to market proprietary products directly in the U.S. - **Forward Integration**: Caplin owns or controls its distribution networks across 23 countries, with over **22,000 distribution touchpoints**, including retail pharmacies (e.g., 45+ "Caplin" stores in Guatemala) and healthcare facilities. This provides real-time market feedback, better consumer engagement, and improved margins. - **Backward Integration**: - **API development**: Over 90 APIs in development, with two API plants under development—one in **Visakhapatnam (general category)** and another in **Thervoy, Chennai (oncology-focused)**. The goal is to be **70% backward-integrated** in APIs for U.S.-bound products by 2024. - **“China 2.0” Initiative**: Strategic partnerships with Chinese firms to access peptides, biosimilars, and key starting materials (KSMs) for fill-finish operations, reducing dependency on external manufacturing. - **Capital Discipline & Financial Strength**: The company is **debt-free**, cash surplus, and funds all capital expenditure through **internal accruals**. As of FY25, it holds over **₹916 crore in cash reserves**, supporting organic growth and selective inorganic opportunities. --- #### **Geographic Focus** | **Region** | **Revenue Contribution** | **Key Developments** | |----------|------------------------|---------------------| | **Latin America** | ~77% | Core market with strong presence in Central America, Mexico, Chile, Ecuador, etc. First-mover advantage in challenging markets; strong tender wins (e.g., $18M in Guatemala, El Salvador, Nicaragua, and Chile). Established private market presence in Chile. Expanding into Mexico with 35+ products filed. | | **United States** | ~18% | Primary growth engine. Caplin Steriles Limited (CSL) has filed **52 ANDAs** (as of Oct 2025), with 42 approvals. Caplin Steriles USA Inc. (CSU) launched in H1 FY25, generated **$3.2M revenue in first 8 months**, achieved profitability, secured licenses in **49 U.S. states**, and established contracts with all major wholesalers and 30+ IDNs. | | **Africa** | ~5% | Strong foothold in Francophone Africa since early 2000s via its “Stock & Sale” distribution model. Serves 10 countries. | | **Other Regulated Markets** | – | Products approved and launched in **Canada, Australia, UAE, Hong Kong, Chile, Malaysia, and Saudi Arabia**. Expanding in **Brazil, South Africa, and CIS countries**. | --- #### **Product Portfolio & Manufacturing** - **Portfolio Breadth**: - Over **5,000 registered products** globally - **650+ pharmaceutical formulations** across **36 therapeutic segments** - Covers **>65% of WHO Essential Medicines List** - Includes **softgels, injectables (liquid, lyophilized, emulsions), prefilled syringes (PFS), ophthalmic products, RTU bags, inhalers, dermocosmetics, and oncology treatments** - **Branded Generics Growth**: Share increased from **5% (FY15)** to **25% (FY25)**, reflecting strategic shift toward differentiated products with higher margins. - **Manufacturing Infrastructure**: - **6 in-house facilities** in Tamil Nadu, Puducherry, and Andhra Pradesh - **60% in-house production**, 40% outsourced (mostly from China) - Facilities approved by **USFDA, EU-GMP, ANVISA (Brazil), INVIMA (Colombia), COFEPRIS (Mexico)** - Capable of producing all major dosage forms, including **complex injectables, dual-chamber PFS, pre-mix bags, and ready-to-use (RTU) bags** --- #### **Caplin Steriles Limited (CSL) – Regulated Markets Arm** - **ANDA Pipeline (U.S.)**: - **52 ANDAs filed** (as of Oct 2025), up from 48 in May 2025 - **42 approvals** received (up from 38 in Aug 2025) - 13 ANDAs currently under FDA review - Pipeline of **>40 injectable & ophthalmic products** planned for filing in next 4 years - Plans to file **7 Pre-Filled Syringe (PFS) products** in FY26 - Targets **10–12 ANDA approvals in FY26** - **Recent Milestones**: - Secured first approvals for **ophthalmic emulsions (Difluprednate)** and **ready-to-use (RTU) bags (Levetiracetam)** - Commercialized **Injectable Emulsions**, **Plastic Vial formats**, and **RTU Bags** - Acquired 3–4 ANDAs to accelerate pipeline --- #### **U.S. Market Expansion via Caplin Steriles USA Inc. (CSU)** - **Direct Commercial Presence**: - Profitable within first year - Generated **$3.2M revenue in 8 months** - **24 products launched** (vs. 22 in May 2025), with over 15 more in pipeline for FY26 - Supplies to **5,610 healthcare facilities** (hospitals, clinics, pharmacies) - Contracted with **all “Big 4” U.S. wholesalers** and **30+ IDNs/hospital systems** - Aims to maximize **high-margin B2C and direct sales** to reduce reliance on milestone-based B2B income - **Strategic Shift**: - Moving from **B2B licensing and partnerships** to **own-label brand presence** - Replicating Latin American "direct-to-customer" model in the U.S., targeting **underserved healthcare providers** rather than competing for GPO contracts --- #### **R&D & Innovation** - **Investment**: - **₹89 crore in R&D in FY25**, highest ever (~4.6% of revenue) - Over **₹900 crores invested in R&D over the past decade** - Among top R&D spenders in Indian pharma - **Focus Areas**: - **Complex injectables**: Suspensions, emulsions, lyophilized vials, PFS, RTU bags - **Oncology**: 100+ oncology product approvals in Central America; first insulin product approved in Central America - **Niche Devices**: Dual-chamber pre-filled syringes, auto-injectors - **Biosimilars**: Launching **GLP-1 products** via fill-finish model using Chinese KSMs - **R&D Infrastructure**: - **Dedicated R&D centers** in Chennai, Hyderabad, Chengalpattu - **CRO division (Amaris Clinical)** with 72-bed bioequivalence facility (DGCI, FDA-compliant) - Completed **>100 BE/BA studies**, supporting filings in Latin America and the U.S. --- #### **Financial Highlights (FY25)** - **Revenue**: ₹2,034 crore (~$244M) - **R&D Expenditure**: ₹89 crore (~$10.7M) - **Cash Reserves**: ₹916 crore (~$110M) - **Employees**: ~3,500 (direct + indirect) - **Manufacturing Sites**: 6 in India; partner facilities in China --- #### **Key Differentiators** 1. **First-Mover in Challenging Markets**: Strong leadership in Latin America and Africa via early entry and direct distribution. 2. **End-to-End Integration**: Full vertical integration from KSMs to pharmacies. 3. **Negative Working Capital Model**: Enhances cash flow and capital efficiency. 4. **Asset-Light Strategy**: Strategic outsourcing improves cost control. 5. **U.S. FDA-Compliant Sterile Manufacturing**: One of few Indian mid-sized companies with a dedicated injectables plant exporting under its own ANDAs. 6. **First Indian Company** to produce **dual-chamber prefilled syringes** for Latin America post-INVIMA approval. ---